Aim: The COVID-19 pandemic has negatively affected the whole world and health systems. Although the literature includes recommendations regarding the timing of Percutaneous endoscopic gastrostomy (PEG) in COVID-19 patients, there are no significant clinical studies yet. Therefore, we aim to contribute to the literature by sharing our data on this subject. Materials and Methods: Patients who underwent PEG between March 2020 and March 2021 were retrospectively evaluated in our clinic. The patients were compared statically in terms of age, gender, medical indications, comorbid diseases, hospitalization in the intensive care unit (ICU), blood tests, and post-intervention complications. PEG was inserted routinely in PCR-negative patients. Patients who underwent PEG were compared as outpatients and inpatients in the ICU. Moreover, patients who underwent PEG while hospitalized in the ICU were divided into two groups according to the presence of COVID-19 infection; patients noninfected with COVID-19 (group 1) and COVID-19 infected patients (group 2). Results: PEG was performed in 66 patients during the COVID-19 pandemic. These patients predominantly consisted of those with SVH, Alzheimer's, or traumatic brain injury. In the present study, thirty-two (%48.5) patients were female with a mean age of 69.4±17.6, and forty-seven patients underwent PEG in the ICU. Furthermore, eleven of these patients were COVID-19, infected patient group (group-2). There was no statistical difference in blood albumin levels, CRP, hemogram results, and 30-day mortality results between group 1 and group 2 (P>0.05). Conclusion: PEG is a minimally invasive intervention that is commonly used for enteral feeding. The timing of the procedure is crucial for inpatients with COVID-19. Although the most appropriate timing is the 30th day after the COVID-19 infection process, we think that PEG may insert on the 10th day in eligible patients.